Reports Q4 revenue $136.5M, consensus $134.1M. "We are poised for a transformative year in 2023. Our increasingly profitable NUPLAZID franchise supports future growth opportunities, including trofinetide – which has the potential to become our second marketed product – as well as the development of our pipeline," said Steve Davis, CEO. "Last year we submitted our New Drug Application for trofinetide for the treatment of Rett syndrome and we are eager to get to our PDUFA action date of March 12, 2023. Importantly, we also advanced our Phase 3 negative symptoms of schizophrenia program and introduced ACP-204, a new molecule that we plan to evaluate in patients with Alzheimer’s disease psychosis later this year."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACAD:
